BH_NonClinical_Pharmacy_Car-T

{
  "awards": [
    {
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2030-12-05T23:59:59Z",
        "maxExtentDate": "2035-12-07T23:59:59Z",
        "startDate": "2025-12-08T00:00:00Z"
      },
      "documents": [
        {
          "datePublished": "2025-11-26T09:46:27Z",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "format": "text/html",
          "id": "077086-2025",
          "noticeType": "UK5",
          "url": "https://www.find-tender.service.gov.uk/Notice/077086-2025"
        }
      ],
      "hasOptions": true,
      "hasRenewal": true,
      "id": "1",
      "items": [
        {
          "additionalClassifications": [
            {
              "description": "Medical equipments, pharmaceuticals and personal care products",
              "id": "33000000",
              "scheme": "CPV"
            },
            {
              "description": "Pharmacy services",
              "id": "85149000",
              "scheme": "CPV"
            }
          ],
          "id": "1",
          "relatedLot": "1"
        }
      ],
      "mainProcurementCategory": "services",
      "milestones": [
        {
          "dueDate": "2025-12-08T23:59:59Z",
          "id": "1",
          "status": "scheduled",
          "type": "futureSignatureDate"
        }
      ],
      "options": {
        "description": "Extension option"
      },
      "relatedLots": [
        "1"
      ],
      "renewal": {
        "description": "Option to extend contract by a further 5 years"
      },
      "status": "pending",
      "suppliers": [
        {
          "id": "GB-COH-02487574",
          "name": "Bristol Myers Squibb"
        }
      ],
      "title": "Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products",
      "value": {
        "amount": 2100000.0,
        "amountGross": 2520000.0,
        "currency": "GBP"
      }
    }
  ],
  "buyer": {
    "id": "GB-PPON-PVTL-5832-LMDG",
    "name": "Barts Health NHS Trust"
  },
  "date": "2025-11-26T09:46:27Z",
  "id": "077086-2025",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-05e8d3",
  "parties": [
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "London",
        "postalCode": "E14 5HJ",
        "region": "UKI42",
        "streetAddress": "20 Churchill Place, Canary Wharf"
      },
      "contactPoint": {
        "email": "oliver.watling@nhs.net"
      },
      "details": {
        "classifications": [
          {
            "description": "Public authority - central government",
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE"
          }
        ],
        "url": "https://www.bartshealth.nhs.uk"
      },
      "id": "GB-PPON-PVTL-5832-LMDG",
      "identifier": {
        "id": "PVTL-5832-LMDG",
        "scheme": "GB-PPON"
      },
      "name": "Barts Health NHS Trust",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Denham",
        "postalCode": "UB8 1DH",
        "region": "UKJ13",
        "streetAddress": "Arc Uxbridge Sanderson Road,   New Denham,"
      },
      "contactPoint": {
        "email": "jon.joyce@bms.com"
      },
      "details": {
        "scale": "large",
        "vcse": false
      },
      "id": "GB-COH-02487574",
      "identifier": {
        "id": "02487574",
        "scheme": "GB-COH"
      },
      "name": "Bristol Myers Squibb",
      "roles": [
        "supplier"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "description": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient\u2019s T cells are genetically modified to target cancer cells.\nThe proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products\nAt the time of writing it is only offered at 8 sites across the UK.\nThe proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.\nThe price paid to the supplier with be capped at NICE / NHS England approved list prices.",
    "documents": [
      {
        "description": "Not published",
        "documentType": "conflictOfInterest",
        "id": "conflictOfInterest"
      }
    ],
    "id": "C402343",
    "legalBasis": {
      "id": "2023/54",
      "scheme": "UKPGA",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
    },
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient\u2019s T cells are genetically modified to target cancer cells.\nThe products can only be supplied by the the proposed contractor, Bristol Myers Squibb.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersIntellectualPropertyExclusiveRights"
      }
    ],
    "status": "complete",
    "title": "BH_NonClinical_Pharmacy_Car-T"
  }
}